NR4A1 and breast carcinoma: For hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, which is the most common subtype of advanced breast cancer, endocrine therapy, as many regimens as possible, is recommended [1].